Rathbones Group PLC Has $6.84 Million Position in Edwards Lifesciences Corporation $EW

Key Points

• Rathbones Group PLC cut its stake by 31.6% in Q3, selling 40,645 shares and leaving 87,971 shares of Edwards Lifesciences valued at about $6.84 million.
• Quarterly results showed an EPS miss—$0.58 vs. a $0.62 consensus—while revenue rose 13.3% year-over-year to $1.57 billion and the company set Q1 2026 EPS guidance of $0.70–$0.76; analysts rate the stock a "Moderate Buy" with an average target of $96.14.
• Insiders have been net sellers, offloading 79,144 shares (~$6.69 million) in the past 90 days (insiders own 0.34%), even as institutional ownership remains high at 79.46% with several funds (e.g., Korea Investment, Natixis, Rhenman) increasing or initiating stakes.

Rathbones Group PLC cut its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 31.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 87,971 shares of the medical research company's stock after selling 40,645 shares during the quarter. Rathbones Group PLC's holdings in Edwards Lifesciences were worth $6,842,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of EW. CreativeOne Wealth LLC lifted its stake in Edwards Lifesciences by 20.6% in the 3rd quarter. CreativeOne Wealth LLC now owns 3,249 shares of the medical research company's stock valued at $253,000 after acquiring an additional 556 shares in the last quarter. Natixis Advisors LLC grew its stake in shares of Edwards Lifesciences by 8.7% during the 3rd quarter. Natixis Advisors LLC now owns 257,302 shares of the medical research company's stock worth $20,010,000 after acquiring an additional 20,574 shares in the last quarter. Korea Investment CORP grew its stake in shares of Edwards Lifesciences by 10.0% during the 3rd quarter. Korea Investment CORP now owns 510,890 shares of the medical research company's stock worth $39,732,000 after acquiring an additional 46,317 shares in the last quarter. Rhenman & Partners Asset Management AB raised its holdings in shares of Edwards Lifesciences by 181.8% in the third quarter. Rhenman & Partners Asset Management AB now owns 155,000 shares of the medical research company's stock valued at $12,054,000 after purchasing an additional 100,000 shares during the last quarter. Finally, Grantham Mayo Van Otterloo & Co. LLC bought a new stake in shares of Edwards Lifesciences in the third quarter worth $1,134,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Price Performance

Shares of EW opened at $81.71 on Monday. The company has a market cap of $47.46 billion, a price-to-earnings ratio of 44.65, a PEG ratio of 2.13 and a beta of 0.93. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89. The company's fifty day simple moving average is $82.56 and its 200 day simple moving average is $81.47. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts' consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. During the same quarter in the prior year, the business earned $0.59 EPS. The business's revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Activity

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,700 shares of the business's stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the transaction, the chief financial officer owned 39,898 shares of the company's stock, valued at $3,370,184.06. The trade was a 16.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the company's stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at $1,885,571.40. This represents a 4.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 79,144 shares of company stock valued at $6,685,688. 0.34% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on EW. Royal Bank Of Canada increased their target price on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an "outperform" rating in a report on Friday, December 5th. JPMorgan Chase & Co. upgraded shares of Edwards Lifesciences from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $90.00 to $100.00 in a research note on Thursday, December 18th. BTIG Research reissued a "buy" rating and set a $103.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. TD Cowen upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating in a report on Friday, January 9th. Finally, Truist Financial set a $89.00 target price on Edwards Lifesciences and gave the company a "hold" rating in a research report on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, Edwards Lifesciences has an average rating of "Moderate Buy" and an average target price of $96.14.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.